reports
Press Release: Sanofi, Formation Bio and OpenAI announce first-in-clas...
Press Release: Sanofi, Formation Bio and OpenAI announce first-in-class AI collaboration Sanofi, Formation Bio and OpenAI announce first-in-class AI collaboration Paris, New York, N.Y., and San Francisco, CA, May 21, 2024. Sanofi, Formation Bio and OpenAI are collaborating to build AI-powered software to accelerate drug development and bring new medicines to patients more efficiently. The three teams will bring together data, software and tuned models to develop custom, purpose-built solutions across the drug development lifecycle. This represents a first collaboration of its kind within...
Communiqué de presse : Sanofi, Formation Bio et OpenAI annoncent une c...
Communiqué de presse : Sanofi, Formation Bio et OpenAI annoncent une coopération de première classe autour de l’IA Sanofi, Formation Bio et OpenAI annoncent une coopération de première classe autour de l’IA Paris, New York, New York et San Francisco, Californie, 21 mai 2024. Sanofi, Formation Bio et OpenAI collaborent afin de construire des logiciels alimentés par l’IA afin d’accélérer le développement de médicaments et de proposer de nouveaux médicaments aux patients de manière plus efficace. Les trois équipes réuniront des données, des logiciels et des modèles adaptés pour développer d...
Sanofi: Information concerning the total number of voting rights and s...
Sanofi: Information concerning the total number of voting rights and shares - April 2024 Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’Autorité des Marchés Financiers (Regulation of the French stock market authority) Sanofia French société anonyme with a registered share capital of 2,529,599,938 €Registered office : 46, avenue de la Grande Armée - 75017 Paris - FranceRegistered at the Paris Commercial and Companies Registry un...
Press Release: Dupixent® late-breaking data from NOTUS confirmatory ph...
Press Release: Dupixent® late-breaking data from NOTUS confirmatory phase 3 COPD study presented at ATS and published in NEJM Dupixent® late-breaking data from NOTUS confirmatory phase 3 COPD study presented at ATS and published in NEJM NOTUS results confirm landmark data from the phase 3 BOREAS study and show Dupixent significantly reduced exacerbations by 34% and improved lung function, compared to placebo, in uncontrolled chronic obstructive pulmonary disease (COPD) with evidence of type 2 inflammationData support the potential of Dupixent as the first new treatment approach in mo...
Communiqué de presse : Présentation à l’ATS et publication dans le NEJ...
Communiqué de presse : Présentation à l’ATS et publication dans le NEJM des données de dernière heure de l’étude confirmatoire de phase III NOTUS relative à Dupixent® dans le traitement de la BPCO Présentation à l’ATS et publication dans le NEJM des données de dernière heure de l’étude confirmatoire de phase III NOTUS relative à Dupixent® dans le traitement de la BPCO Les résultats de l’étude NOTUS confirment les données décisives de l’étude de phase III BOREAS et montrent que, dans le traitement de la bronchopneumopathie chronique obstructive (BPCO) avec signature inflammatoire de ty...
Novo Nordisk A/S - share repurchase programme
Novo Nordisk A/S - share repurchase programme Bagsværd, Denmark, 17 May 2024 – On 6 May 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 20 billion to be executed during a 12-month period beginning 6 February 2024. Under the programme initiated 6 May 2024, Novo Nordisk will repurchase B share...
Vat Group Ag: 1 director
A director at Vat Group Ag sold 325 shares at 476.000CHF and the significance rating of the trade was 62/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly show...
Publicis Groupe : Le Comité de Nomination émet ses recommandations dan...
PARIS--(BUSINESS WIRE)-- Regulatory News: Dans le cadre de l'évolution de la gouvernance de la Société, proposée par le Conseil de Surveillance, le Comité de Nomination de Publicis Groupe (Paris:PUB) [Euronext Paris FR0000130577, CAC 40] s'est réuni, ce jour, sous la présidence de Madame Elisabeth Badinter, afin de recommander les nominations suivantes : André Kudelski en tant qu'Administrateur Référent. A ce titre, il aura pour principales missions de s’assurer du bon fonctionnement des organes de gouvernance de la Société aux côtés du Président du Conseil d'Administration, de présider d...
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, exe...
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons Bagsværd, Denmark, 15 May 2024 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse. The company’s board members, executives and their associated persons have reported the transactions to Novo Nordisk and have given Novo Nordisk power of attorney on their behalf to publish trading in Novo Nordisk shares...
VAT Group AG Generalversammlung 2024: Aktionärinnen und Aktionäre gene...
VAT Group AG / Schlagwort(e): Generalversammlung VAT Group AG Generalversammlung 2024: Aktionärinnen und Aktionäre genehmigten alle Anträge des Verwaltungsrats und eine unveränderte Dividende von CHF 6.25 pro Aktie 14.05.2024 / 17:13 CET/CEST Die Aktionärinnen und Aktionäre der VAT Group AG haben an der heutigen ordentlichen Generalversammlung (GV) allen Anträgen des Verwaltungsrats zugestimmt, einschliesslich der Ausschüttung einer unveränderten Dividende von CHF 6.25 pro Aktie. An der Versammlung in St.Gallen waren 351 Aktionärinnen und Aktionäre anwesend, die 67.82% Proz...
VAT Group AG Annual General Meeting 2024: Shareholders approved all Bo...
VAT Group AG / Key word(s): AGMEGM VAT Group AG Annual General Meeting 2024: Shareholders approved all Board proposals and unchanged dividend of CHF 6.25 per share 14.05.2024 / 17:13 CET/CEST The shareholders of VAT Group AG approved all motions proposed by the Board of Directors at today’s ordinary Annual General Meeting (AGM), including the payout of an unchanged dividend of CHF 6.25 per share. 351 shareholders representing 67.82% percent of the company’s share capital were present at the meeting held in St.Gallen. The shareholders re-elected Dr. Martin Komischke as Chai...
Nannette LaFond-Dufour rejoint Publicis Groupe en tant que Chief Impac...
PARIS--(BUSINESS WIRE)-- Regulatory News: Publicis Groupe (Paris:PUB) [Euronext Paris FR0000130577, CAC 40] annonce la nomination de Nannette LaFond-Dufour en tant que Chief Impact Officer. Dans ce rôle global nouvellement créé, Nannette LaFond-Dufour aura la responsabilité de tous les engagements ESG du Groupe : des objectifs climatiques ambitieux de Publicis approuvés par le SBTi, à son plan d’actions concret en termes de diversité, d’égalité et d’inclusion, en passant par ses initiatives emblématiques telles que Working with Cancer et le Women’s Forum for the Economy & Society. Derniè...
Nannette LaFond-Dufour joins Publicis Groupe as Chief Impact Officer
Nannette LaFond-Dufour joins Publicis Groupe as Chief Impact Officer Nannette LaFond-Dufour joins Publicis Groupeas Chief Impact Officer May 14, 2024 - Paris – Publicis Groupe [Euronext Paris FR0000130577, CAC 40] today announced the appointment of Nannette LaFond-Dufour as Chief Impact Officer. In this newly created global role, Nannette will be responsible for driving immediate impact across the Groupe’s long-term ESG commitments. These include Publicis’ ambitious SBTI-approved climate goals, its concrete diversity, equity and inclusion action plans, as well as ...
Nannette LaFond-Dufour rejoint Publicis Groupe en tant que Chief Impac...
Nannette LaFond-Dufour rejoint Publicis Groupe en tant que Chief Impact Officer Nannette LaFond-Dufour rejoint Publicis Groupe en tant que Chief Impact Officer Paris, le 14 mai 2024 - Paris – Publicis Groupe [Euronext Paris FR0000130577, CAC 40] annonce la nomination de Nannette LaFond-Dufour en tant que Chief Impact Officer. Dans ce rôle global nouvellement créé, Nannette LaFond-Dufour aura la responsabilité de tous les engagements ESG du Groupe : des objectifs climatiques ambitieux de Publicis approuvés par le SBTi, à son plan d’actions concret en termes de dive...
- Stephane Beyazian
- Stephane Beyazian
- Damien Choplain
- Martial Descoutures
Novo Nordisk : Mim8 officially in competition with Hemlibra
>Positive results for the FRONTIER2 trial evaluating Mim8 in haemophilia A - Novo reported yesterday evening the clinical results of its phase 3 trial evaluating Mim8 in haemophilia A. Some 250 patients with haemophilia A and with or without inhibitors were included in the trial. The primary endpoint was to demonstrate control of bleeding episodes. Note that this trial was structured between 2 patient cohorts: one with no initial prophylaxis treatment treatment (n=57)...
- Damien Choplain
- Martial Descoutures
Novo Nordisk : Mim8 officiellement en concurrence avec Hemlibra
>Résultats positifs de l’essai FRONTIER2 évaluant Mim8 en hémophilie A - Novo publiait hier soir les résultats cliniques de son essai de phase 3 évaluant Mim8 en hémophilie A. 250 patients atteints d’hémophilie A présentant ou non des inhibiteurs étaient inclus dans cet essai. Le critère primaire est de démontrer un contrôle des saignements. Il faut noter que cet essai a été structuré entre 2 cohortes de patients : l’une ayant initialement aucune prophylaxie (n=57) et...
- Dominic Rose
- Naresh Chouhan
AZN - The Path to 2030 Revenue of >$80bn (BUY, TP £140 [£125], 12pgs)
There has been much investor discussion of the upside potential to consensus that could happen as a result of new long-term revenue guidance at the CMD next Tuesday. We show on a product-by-product basis how Total Revenues could exceed $80bn by 2030. This would imply a 25% U/G to consensus revenue forecasts & considerably more to EPS. We do however caution investors that to get to this revenue forecast, it will require considerable R&D investment and we do not believe that consensus has factored...
Novo Nordisk A/S: Once-weekly and once-monthly Mim8 demonstrate superi...
Novo Nordisk A/S: Once-weekly and once-monthly Mim8 demonstrate superior reduction of treated bleeding episodes compared to on-demand and prior prophylaxis treatment in people with haemophilia A in the Frontier 2 trial Bagsværd, Denmark, 13 May 2024 – Novo Nordisk today announced the headline results from the FRONTIER 2 trial, a pivotal phase 3a, 26-week open-label, randomised, controlled, multi-arm trial in 254 people. The trial investigated the efficacy and safety of once-weekly and once-monthly subcutaneous Mim8 versus no prophylaxis and versus prior coagulation factor prophylaxis treatm...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.